Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)

B. B.Y. Ma, B. C. Goh, W. T. Lim, E. P. Hui, E. H. Tan, G. De Lima Lopes, K. W. Lo, L. Li, H. Loong, N. R. Foster, C. Erlichman, A. D. King, M. K.M. Kam, S. F. Leung, K. C. Chan, A. T.C. Chan

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)'. Together they form a unique fingerprint.

Medicine & Life Sciences